Advertisement

U.S. markets closed

S&P Futures
6,004.50
+0.75(+0.01%)
Dow Futures
43,923.00
+13.00(+0.03%)
Nasdaq Futures
21,222.75
-2.00(-0.01%)
Russell 2000 Futures
2,399.00
+3.30(+0.14%)
Crude Oil
72.12
-0.24(-0.33%)
Gold
2,708.10
+2.30(+0.09%)

Camurus AB (7CA.BE)

Berlin - Berlin Delayed Price. Currency in EUR

51.90

+0.70

(+1.37%)

At close: 08:16AM CET

Loading interactive chart...

Clinical Trials Arena
Camurus reports positive results from Phase III trial of acromegaly treatment
The trial's primary focus was on safety over a year of treatment, with CAM2029 demonstrating a favourable profile.
PR Newswire
Camurus announces positive Phase 3 results from the ACROINNOVA 2 study of octreotide SC depot (CAM2029) in acromegaly patients
Camurus (NASDAQ: CAMX) (STO: CAMX) today announced positive, final, topline results from the 52-week Phase 3 open-label ACROINNOVA 2 (NCT04125836) study, which evaluated safety and efficacy of the company's once-monthly octreotide subcutaneous (SC) depot (CAM2029). The study included a total of 135 patients with acromegaly who were biochemically controlled (IGF-1≤1xULN) or uncontrolled on stable doses of standard-of-care (SoC) with first generation somatostatin ligands (SRL) at screening; of the